

May 1, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** Robert Taylor Segraves, M.D., Ph.D.  
**Role(s) in Work Group:** Member, Sexual and Gender Identity Disorders Work Group  
**Institutional Affiliation(s):** Case School of Medicine, MetroHealth Medical Center  
**City, State:** Cleveland, OH

**Biographical Sketch:**  
**Robert Taylor Segraves, M.D., Ph.D.**

Dr. Segraves is professor of psychiatry at Case Western Reserve School of Medicine and chair of the department of psychiatry at metroHealth medical Center. Among his scientific interests are the treatment of sexual disorders, the co-morbidity of sexual dysfunction with anxiety and depressive disorders, sexual side effects of pharmacological agents, and pharmacotherapy of sexual disorders. He has authored or co-authored over 70 peer reviewed manuscripts and has co-edited five texts in the area of sexual medicine. He was a member of the DSM III-R, DSM IV and DSM IV TR task forces on sexual disorders. He is editor of the Journal of Sex and Marital Therapy and on the editorial board of the International Journal of Impotence Research.

Dr. Segraves obtained his B.A. and M.D. from Vanderbilt University, he obtained his PhD from the University of London and he completed his residency in psychiatry at the University of Chicago.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.**

<b>Non-Profit and Advocacy Organizations</b>	<b>Year(s)</b>	<b>Role</b>
National Alliance on Mental Illness-Cleveland	2006-2008	Board member
Ohio Psychiatric Political Action Committee	2002-2008	Board member
Cleveland Psychiatric Society	2008-2009	President

The two tables below represent Dr. Segraves's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of year.

Dr. Segraves has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Astra-Zeneca	2005-2007	3
Bristol Myers	2005-2007	1, 3
Eli Lilly	2005-2007	1,3
Boehringer-Ingelheim	2005-2007	1, 3
Cognimed	2005-2006	1
Novartis	2006	3, 5
Roche	2005-2007	5
Health Research Association	2007	3
Biosante	2007	3
Pfizer	2006	3

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Pfizer	2008	3
Boehringer-Ingelheim	2008	1, 3
New England Research Institute	2008	1
Erectile Dysfunction Information Center	2008	1
Roche	2008	5
Novartis	2008	3, 5